title: Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.
abstract: OBJECTIVE
  To assess the maternal, fetal and neonatal safety of enoxaparin in pregnant women who require antithrombotic therapy.
  
  
  METHODS
  Retrospective analysis of case notes of women who received enoxaparin during pregnancy, irrespective of dose, duration and reason for treatment.
  
  
  METHODS
  Fifty-five French perinatal centres.
  
  
  METHODS
  Data from 624 pregnancies in 604 women between 1988 and 1997. The incidence of previous thromboembolism was 29.8%, known thrombophilia 15.2%.
  
  
  METHODS
  Indication, regimen of enoxaparin and outcome measures were reported for each pregnancy. Information was obtained from case records, validated by research staff and analysed by an independent scientific committee.
  
  
  METHODS
  Incidence, seriousness and causality of maternal, fetal and neonatal adverse events, pregnancy outcome, and incidence of venous thromboembolism.
  
  
  RESULTS
  Enoxaparin was administered for treatment of an acute episode in 49 cases and for thromboprophylaxis in 574 cases. Serious maternal haemorrhage occurred in 11 cases during pregnancy (1.8%), one being reasonably related to enoxaparin, and in nine cases at delivery (1.4%), all unrelated to enoxaparin. Maternal thrombocytopenia was reported in 10 cases (1.6%). two being serious but unrelated to enoxaparin. Eight pregnancies ended in stillbirth (1.1%). Among the 693 live births, 17 major congenital abnormalities (2.5%) and 10 serious neonatal haemorrhages (1.4%) were reported. None of the fetal or neonatal adverse events was related to enoxaparin. Eight venous thromboembolic events (1.3%) were reported.
  
  
  CONCLUSIONS
  The incidence of adverse events reported could be explained by the high risk profile of the study population. Overall, this retrospective study suggests enoxaparin is well tolerated during pregnancy.
authors.affiliation: Service de Gynécologie-Obstétrique, Hôpital Saint Vincent-de-Paul, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Lepercq
authors.forename: J
authors.initials: J
authors.lastname: Conard
authors.forename: A
authors.initials: A
authors.lastname: Borel-Derlon
authors.forename: J Y
authors.initials: JY
authors.lastname: Darmon
authors.forename: O
authors.initials: O
authors.lastname: Boudignat
authors.forename: C
authors.initials: C
authors.lastname: Francoual
authors.forename: P
authors.initials: P
authors.lastname: Priollet
authors.forename: C
authors.initials: C
authors.lastname: Cohen
authors.forename: N
authors.initials: N
authors.lastname: Yvelin
authors.forename: J F
authors.initials: JF
authors.lastname: Schved
authors.forename: M
authors.initials: M
authors.lastname: Tournaire
authors.forename: J Y
authors.initials: JY
authors.lastname: Borg
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D020300:Intracranial Hemorrhages / Q000139:chemically induced; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy*; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced; D013923:Thromboembolism / Q000188:drug therapy*; D020246:Venous Thrombosis / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin